Not applicable.
1. Field of the Invention
This invention relates to metal implants for use in surgical procedures, and in particular to the introduction of a biocidal material into such implants to suppress or control infection.
2. Background of the Invention
Various surgical procedures require the use of implants. For example cancerous bone may be removed, in prosthetic surgery, to be replaced by a metal implant. Such an implant may for example be of titanium alloy, which is very strong and relatively light. To ensure a hard-wearing surface the provision of a titanium nitride coating has been suggested. There is furthermore a risk of introducing infection when implanting such metal implants, and it has been suggested that metallic silver might be electroplated onto metal implants, the silver being a biocidal material that can control infection without causing toxic effects to the patient. However such coatings, whether of titanium nitride or silver, may be undercut due to corrosion from body fluids, so that the coating may detach from the implant, which may increase wear and cause tissue damage.
According to the present invention there is provided an implant for use in a surgical procedure, the implant comprising a metal substrate and a surface layer that is integral with the metal substrate, the layer incorporating a biocidal metal deposited from a solution.
The invention also provides a method of producing such an implant.
The foregoing has outlined rather broadly the features and technical advantages of the present invention in order that the detailed description of the invention that follows may be better understood. Additional features and advantages of the invention will be described hereinafter that form the subject of the claims of the invention. It should be appreciated by those skilled in the art that the conception and the specific embodiments disclosed may be readily utilized as a basis for modifying or designing other embodiments for carrying out the same purposes of the present invention. It should also be realized by those skilled in the art that such equivalent embodiments do not depart from the spirit and scope of the invention as set forth in the appended claims.
Such an integral surface layer may be generated by growing the layer from the metal itself, for example by an anodising process; or alternatively by depositing the layer for example by electroplating, followed by diffusion bonding so that the layer becomes integral with the metal of the implant. Anodising forms an adherent oxide layer, although if it is carried out in phosphoric acid then a phosphate may be formed. Such an adherent phosphate layer may also be modified to form a hydroxyapatite layer, which can stimulate bone growth.
The biocidal material should preferably be effective for at least 6 weeks, preferably for up to 6 months after surgery, and the release rate should be low to avoid toxic effects on body cells. Furthermore the total quantity of biocidal material is preferably also limited to minimize any toxic effects.
It is also desirable if the surface is highly polished before production of the surface layer. This may for example be achieved by electropolishing.
In principle, a range of different metals may be used for the biocidal metal. In particular, if the layer is a metal layer deposited by electroplating then it clearly must be stable to corrosion. Gold, platinum, iridium and palladium would be potentially suitable, although expensive; silver is preferable as it is not particularly soluble in body fluids due to the presence of chloride ions and the low solubility of silver chloride. If the surface layer contains the biocidal metal in ionic form, then a wider range of metals would be possible. In addition to the elements already mentioned, copper, tin, antimony, lead, bismuth and zinc might be used as ions combined into an insoluble matrix for example of metal oxide or metal phosphate. The rate of release would be controlled, in this case, primarily by the strength of the absorption of the metal ions in the matrix.
The metals that may be used to make such prosthetic implants are typically a form of stainless steel, a titanium alloy, or a cobalt/chromium alloy, although zirconium could also be used. The standard alloys for this purpose are titanium 90% with 6% aluminum and 4% vanadium (British standard 7252), or chromium 26.5-30%, molybdenum 4.5-7%, and the remainder cobalt (British standard 7252 part 4).
Preferably the implant is initially polished to provide a very smooth surface. Both stainless steel (chromium/iron/nickel) and cobalt/chromium alloy can be electro-polished using as electrolyte a mixture of phosphoric acid and glycerine, or a mixture of phosphoric acid and sulphuric acid. Titanium alloy can be electro-polished using acetic acid, or a mixture of nitric and hydrofluoric acids. Alternatively the implants might be subjected to a combination of anodic passivation with mechanical polishing, which may be referred to as electrofinishing, this process removing the oxide that protects surface roughness, the surface at that point then being electrochemically re-passivated, so producing a mirror-smooth finish. Various electrolytes are suitable for this purpose, including nitric acid mixed with sulphuric acid, sodium hydroxide, sodium phosphate, or sodium hydroxide mixed with sodium nitrate.
After polishing the surface of the metal, either silver deposition or surface conversion can take place. Considering surface conversion first, a layer of metal oxide or phosphate may be formed by anodising in a suitable electrolyte, so that the oxide or phosphate layer builds out from the surface of the metal. Biocidal metal ions can then be absorbed from an aqueous salt solution into the oxide or phosphate matrix, for example the ions Ag+ or Cu++. Cations of palladium, platinum or even ruthenium could be absorbed in a similar way. If desired, deposited silver, platinum or palladium ions could then be converted to metal, or deposited ruthenium ions converted to insoluble RuO2, within the oxide or phosphate surface coating, this reaction being performed chemically or electrochemically or by light.
Considering now silver deposition, the coating should be thin to prevent toxic effects. A high degree of adherence to the underlying metal can be ensured by first removing the surface oxide layer by anodic etching, followed by a brief reversal of polarity in the presence of appropriate ions, so as to cover the surface with a thin coating of silver. This may be repeated to ensure there are no pin-holes. The plating electrolyte may include hydrofluoric acid, or may be an alkaline cyanide electroplating electrolyte. After deposition, the silver coating should be diffusion bonded so as to form an inter-metallic layer, by heating the implant to an elevated temperature. Typically it should be heated to above 800° C., preferably between 810° C. and 950° C., in an inert atmosphere for example of argon for a period of between 1 and 6 hours. This substantially eliminates the risk of coating delamination. However with titanium-based implants the temperature must not exceed 850° C. as titanium would undergo a phase change from alpha to beta form above this temperature.
In place of silver, other metals such as platinum or palladium may be electro-deposited and then thermally treated in a similar fashion so as to form an inter-metallic layer.
The invention will now be further and more particularly described, by way of example only.
A hip implant is made of titanium alloy (Ti/Al/V). The implant is cleaned ultrasonically using first acetone as the liquid phase, and then a 1 M aqueous solution of sodium hydroxide, and is then rinsed in de-ionised water. The cleaned implant is then immersed in a stirred 12 weight % solution of phosphoric acid, and is anodised for 2 hours at a maximum voltage of 10 V and a maximum current of 10 mA/cm2, so as to form a surface coating of titanium phosphate. It is then rinsed in de-ionised water again. The surface, which is initially pale grey, turns to a darker matte grey as a consequence of the anodising, with a slightly yellow hue.
The implant is then immersed in a stirred 0.1 M aqueous solution of silver nitrate, and left for 2 hours. As a result of ion exchange there is consequently some silver phosphate in the titanium phosphate coating. The implant is then ready to be implanted. During exposure to body fluids there will be a slow leaching of silver ions from the phosphate layer, so that any bacteria in the immediate vicinity of the implant are killed. Infection arising from the implant is therefore suppressed.
Experimental samples of this titanium alloy were cleaned, anodised to form a layer of titanium phosphate, and then subjected to ion exchange to form silver phosphate, following the procedure described above. One sample was placed in direct daylight for 110 hours; the exposed surface became darkened as a result of this exposure to daylight, indicating the formation of silver metal by photo-reduction. The other sample was immersed in a solvent containing a mixture of 4 M nitric acid and 0.5 M sodium fluoride (equivalent to hydrofluoric acid) to dissolve the coating. The dark grey surface coating was removed completely within 3 minutes, leaving a silver-grey finish. The resulting solution was analyzed for the presence of silver by atomic absorption spectrometry, and the concentration of silver was found to be equivalent to an average surface loading of 73 μg/cm2.
Although the present invention and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations may be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
Number | Date | Country | Kind |
---|---|---|---|
0208642.9 | Apr 2002 | GB | national |
This application is a divisional application of U.S. patent application Ser. No. 10/501,538, entitled “Metal Implants,” filed on Jul. 16, 2004, the entire disclosure of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3852045 | Wheeler et al. | Dec 1974 | A |
4027393 | Ellis et al. | Jun 1977 | A |
4263681 | Notton | Apr 1981 | A |
4336617 | Shikita et al. | Jun 1982 | A |
4476590 | Scales et al. | Oct 1984 | A |
4784160 | Szilagyi | Nov 1988 | A |
4806218 | Hemminger et al. | Feb 1989 | A |
4813965 | Roberts | Mar 1989 | A |
4818572 | Shimamune et al. | Apr 1989 | A |
4843965 | Merzals | Jul 1989 | A |
4846837 | Kurze | Jul 1989 | A |
4938409 | Roberts | Jul 1990 | A |
5032129 | Kurze et al. | Jul 1991 | A |
5132003 | Mitani | Jul 1992 | A |
5185075 | Rosenberg et al. | Feb 1993 | A |
5211663 | Kovacs et al. | May 1993 | A |
5211832 | Cooper et al. | May 1993 | A |
5310464 | Redepenning | May 1994 | A |
5454886 | Burrell et al. | Oct 1995 | A |
5468562 | Farivar et al. | Nov 1995 | A |
5478237 | Ishizawa | Dec 1995 | A |
5482731 | Vargas-Gutierrez et al. | Jan 1996 | A |
5492763 | Barry et al. | Feb 1996 | A |
5503704 | Bower et al. | Apr 1996 | A |
5520664 | Bricault, Jr. et al. | May 1996 | A |
5612049 | Li et al. | Mar 1997 | A |
5695857 | Burrell et al. | Dec 1997 | A |
5723038 | Scharnweber et al. | Mar 1998 | A |
5753251 | Burrell et al. | May 1998 | A |
5753322 | Yamaguchi et al. | May 1998 | A |
5770255 | Burrell et al. | Jun 1998 | A |
5833463 | Hurson | Nov 1998 | A |
5837275 | Burrell et al. | Nov 1998 | A |
5855612 | Ohthuki et al. | Jan 1999 | A |
5958440 | Burrell et al. | Sep 1999 | A |
5985308 | Burrell et al. | Nov 1999 | A |
6017553 | Burrell et al. | Jan 2000 | A |
6066392 | Hisamoto et al. | May 2000 | A |
6113636 | Ogle | Sep 2000 | A |
6180162 | Shigeru et al. | Jan 2001 | B1 |
6190407 | Ogle et al. | Feb 2001 | B1 |
6191192 | Monden et al. | Feb 2001 | B1 |
6267782 | Ogle et al. | Jul 2001 | B1 |
6322588 | Ogle et al. | Nov 2001 | B1 |
6361567 | Dearnaley | Mar 2002 | B1 |
6365220 | Burrell et al. | Apr 2002 | B1 |
6423468 | Hotta et al. | Jul 2002 | B1 |
6482444 | Bellantone et al. | Nov 2002 | B1 |
6509057 | Shigeru et al. | Jan 2003 | B2 |
6530951 | Bates et al. | Mar 2003 | B1 |
6544288 | Osaka et al. | Apr 2003 | B2 |
6582715 | Barry et al. | Jun 2003 | B1 |
6663634 | Ahrens et al. | Dec 2003 | B2 |
6689170 | Larsson et al. | Feb 2004 | B1 |
6719987 | Burrell et al. | Apr 2004 | B2 |
6866859 | Trogolo et al. | Mar 2005 | B2 |
6913617 | Reiss | Jul 2005 | B1 |
7029566 | Yen | Apr 2006 | B2 |
7048541 | Hall et al. | May 2006 | B2 |
7192445 | Ellingsen et al. | Mar 2007 | B2 |
7270721 | Hilfenhaus | Sep 2007 | B2 |
7291762 | Flick | Nov 2007 | B2 |
7452566 | Sul | Nov 2008 | B2 |
7488343 | O'Brien et al. | Feb 2009 | B2 |
20020099449 | Speitling | Jul 2002 | A1 |
20030045941 | Lewallen | Mar 2003 | A1 |
20030091612 | Sabesan | May 2003 | A1 |
20040116551 | Terry | Jun 2004 | A1 |
20040121290 | Minevski et al. | Jun 2004 | A1 |
20040161473 | Joshi | Aug 2004 | A1 |
20040234604 | Mecking et al. | Nov 2004 | A1 |
20040236338 | Hall | Nov 2004 | A1 |
20050177248 | Hall | Aug 2005 | A1 |
20050221259 | Anderson | Oct 2005 | A1 |
20060035039 | Ylitalo et al. | Feb 2006 | A1 |
20060198903 | Storey et al. | Sep 2006 | A1 |
20070051632 | Sato et al. | Mar 2007 | A1 |
20070187253 | Gilbert et al. | Aug 2007 | A1 |
20080011613 | Wang | Jan 2008 | A1 |
20090035722 | Balasundaram et al. | Feb 2009 | A1 |
20090093881 | Bandyopadhyay et al. | Apr 2009 | A1 |
20090104242 | Karlinsey | Apr 2009 | A1 |
20090124984 | Hanawa | May 2009 | A1 |
20090155335 | O'Shaughnessey et al. | Jun 2009 | A1 |
20090164027 | Zipprich | Jun 2009 | A1 |
20090198344 | Prentice et al. | Aug 2009 | A1 |
20090204213 | Liao et al. | Aug 2009 | A1 |
Number | Date | Country |
---|---|---|
731730 | Apr 2001 | AU |
731732 | Apr 2001 | AU |
62807 | Aug 2000 | BG |
2136456 | Jun 1999 | CA |
00257923 | Jan 1992 | EP |
0555004 | Aug 1993 | EP |
0761182 | Mar 1998 | EP |
00875146 | Jul 2002 | EP |
1207220 | Jan 2008 | EP |
2072514 | Oct 1981 | GB |
2073024 | Oct 1981 | GB |
2136448 | Sep 1984 | GB |
58-167798 | Oct 1983 | JP |
62-182298 | Aug 1987 | JP |
10-158889 | Jun 1998 | JP |
10-168597 | Jun 1998 | JP |
10-168598 | Jun 1998 | JP |
11-181596 | Jul 1999 | JP |
11-181596 | Jul 1999 | JP |
11-209895 | Aug 1999 | JP |
11-229186 | Aug 1999 | JP |
11-236699 | Aug 1999 | JP |
11-302570 | Nov 1999 | JP |
11-343592 | Dec 1999 | JP |
2005287985 | Oct 2005 | JP |
10-0910064 | Jul 2009 | KR |
2167526 | May 2001 | RU |
875146 | Dec 2002 | SI |
WO 8102667 | Oct 1981 | WO |
WO 8102668 | Oct 1981 | WO |
WO 9211043 | Jul 1992 | WO |
WO 9307924 | Apr 1993 | WO |
WO 9513704 | May 1995 | WO |
WO 9518637 | Jul 1995 | WO |
WO 9851231 | Nov 1998 | WO |
WO 9901089 | Jan 1999 | WO |
WO 9926666 | Jun 1999 | WO |
WO 0045724 | Aug 2000 | WO |
WO 0051659 | Sep 2000 | WO |
WO 0064505 | Nov 2000 | WO |
WO 0072777 | Dec 2000 | WO |
WO 0112246 | Feb 2001 | WO |
WO 02096475 | Dec 2002 | WO |
WO 03003938 | Jan 2003 | WO |
WO 03039609 | May 2003 | WO |
WO 03089023 | Oct 2003 | WO |
WO 03094774 | Nov 2003 | WO |
WO 2004002543 | Jan 2004 | WO |
WO 2005087982 | Sep 2005 | WO |
WO 2006058906 | Jun 2006 | WO |
WO 2006104644 | Oct 2006 | WO |
WO 2007050327 | May 2007 | WO |
WO 2007144667 | Dec 2007 | WO |
WO 2008096160 | Aug 2008 | WO |
WO 2009044203 | Apr 2009 | WO |
WO 2009100792 | Aug 2009 | WO |
WO 2009100792 | Aug 2009 | WO |
Entry |
---|
T. Shibata et al, “The effect of temperature on the growth of anodic oxide film on titanium”, Corrosion Science, vol. 37, No. 1, pp. 133-144, 1995. |
T. Shibata et al, “The effect of film formation conditions on the structure and composition of anodic oxide films on titanium”, Corrosion Science, vol. 37, No. 2, pp. 253-270, 1995. |
X. Zhu et al, “Anodic oxide films containing Ca and P of titanium biomaterial”, Biomaterials, 22 (2001) 2199-2206. |
Afshar, “Evaluation of electrical breakdown of anodic films on titanium in phosphate-base solutions”, 2004. |
Aladjem, “Review anodic oxidation of titanium and its alloys”, 1973. |
Aerospace Material Spec. (AMS 2487A), “Anodic treatment of titanium alloys solution pH 12.4 maximum”, 1993-2006. |
Aerospace Material Spec. (AMS 2488D), “Anodic treatment 13 titanium and titanium alloys solution pH 13 or higher”, 1977-2006. |
Chen, “Surface chemistry of TiCl4 on W(100)”, 1996. |
Chi, “Antibacterial activity of anodized aluminum with deposited silver”, 2002. |
Disegi, “Anodizing treatments for titanium implants”, 1997. |
Dunn, “Anodized layers on titanium and titanium alloy orthopedic materials for antimicrobial activity applications”, 1992. |
Dunn, “Formation and characterization of anodized layers on CP Ti and Ti-6Al-4OV”, 1992. |
Dunn, “Gentamicin sulfate attachment and release from anodized Ti-6Al-4V orthopedic materials”, 2004. |
Edwards, “Coating and surface treatment systems for metals”, 1997. |
Kawashita, “Bonelike apatite formation on anodically oxidized titanium metal in simulated body fluid”, 2004. |
Khadiri, “Characterization of titanium oxide thin films anodically grown in phosphoric acid”, 2004. |
Kokubo, “Novel bioactive materials with different mechanical properties”, 2003. |
Kurze et al., “Application fields of ANOF layers and composites”, 1986. |
Li et al., “Calcium phosphate formulation within sol-gel prepared titanium in vitro and in vivo”, 1993. |
Li et al., “The role of hydrated silica, titania and alumina in inducing apatite on implants”, 1994. |
Liu, “Surface modification of titanium, titanium alloys, and related materials for biomedical applications”, 2004. |
Marchenoir, “Study of porous layers formed by anodic oxidation of titanium under high voltage” (French), 1980. |
Marchenoir, “Study of porous layers formed by anodic oxidation of titanium under high voltage” (English translation), 1980. |
Martini, “Detach{grave over (m)}ent of titanium & fluorhydroxypatite particles”, 2003. |
Necula, “In vitro antibacterial >activity of porous TiO2-Ag composite layers against methicillin-resistant Staphylococcus aureus”, 2009. |
Olier, “Influence of the preparation conditions of titanium surfaces on the formation of anodic oxide layers” (French), 1980. |
Olier, “Influence of the preparation conditions of titanium surfaces on the formation of anodic oxide layers” (English translation), 1980. |
Schierholz, “Efficacy of silver-coated medical devices”, 1998. |
Schreckenbach, “Characterization of anodic spark-converted titanium surfaces for biomedical applications”, 1999. |
Shirkhanzadeh, “Bioactive delivery systems for the slow release of antibiotics . . . ”, 1995. |
Shirkhanzadeh, “Nanoporous alkoxy-derived titanium oxide coating”, 1998. |
Souza, “EIS characterization of Ti anodic oxide porous films formed using modulated potential”, 2007. |
Suzuki et al., “Surface treatment of titanium (part 4) in vitro biocompatibility of titanium treated by the anodic spark oxidation”, 1991. |
Takasaki, “Elution of silver ions from A-type zeolite supporting silver ions in aqueous solutions” (Japanese), 1996. |
Takasaki, “Elution of silver ions from A-type zeolite supporting silver ions in aqueous solutions” (English translation), 1996. |
Tsukada, “Low-temperature electrochemical systhesis of ZrO2 films on zirconium substrates”, 1997. |
Xie, “Improvement of surface bioactivity on titanium by water and hydrogen plasma immersion ion implantation”, 2005. |
Yang, “Preparation of bioactive titanium metal via anodic oxidation treatment”, 2004. |
Yoshinari, “Influence of surface modifications to titanium on antibacterial activity in vitro”, 2001. |
Yu, “Synthesis and characterization of phoshated meso porous titanium dioxide with photocatalytic activity”, 2003. |
Yue, “Bioactive titanium metal surfaces with antimicrobial properties prepared by anodic oxidation treatment”, 2009. |
C. Larrson et al., “Bone Response to Surface Modified Titanium Implants: Studies on Electropolished Implants with Different Oxide Thicknesses and Morphology”, Biomaterials 1994, vol. 15, No. 13, pp. 1062-1074. |
C. Larrson et al., “Bone Response to Surface-Modified Titanium Implants: Studies on the Early Tissue Response to Machined and Electropolished Implants with Different Oxide Thicknesses”, Biomaterials 1996, vol. 17, No. 6, pp. 605-616. |
Number | Date | Country | |
---|---|---|---|
20100032309 A1 | Feb 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10501538 | US | |
Child | 12539028 | US |